Novel, primarily small molecule, agents have been developed at Leeds to modulate disease pathways in multiple therapeutic areas.
Many of the therapeutics, which are active against targets identified at Leeds, originated with the Medicinal Chemistry and Chemical Biology (MCCB) Technology Group at the University.
The MCCB group provides a comprehensive and integrated medicinal chemistry, high-throughput screening, and molecular modelling capability for the identification of novel small molecule therapeutics and probes.
A primary aim of the group is to pump-prime projects via the provision of suitable resources such that projects are suitable to go forward for major external grant funding involving the MCCB group as a collaborator.
Examples of therapeutic areas under investigation
Translational funding for drug discovery research
|1. Have target of interest, no compounds||Development pathway 1, Funding Links #1|
|2. Have target of interest & compounds but willing to explore more||Development pathway 2, Funding Links #2|
|3. Have target of interest & compounds/series to develop. No interest in other compounds.||Development pathway 3, Funding Links #3|
|4. Non small-molecule project||Development pathway 4, Funding Links #4|